Novartis joined industry associations in expressing concerns over the impact that a ‘hard’ or ‘disorderly’ Brexit could have on the life sciences sector.
China-based CDMO (contract development and manufacturing organization) WuXi PharmaTech has raised about $80m for subsidiary SynTheAll Pharmaceutical Co. (STA) via the private placement of 7.16m common shares of STA stock.
Quintiles has completed its previously announced refinancing in which it entered into new senior secured credit facilities totaling $1.95bn, consisting of a $500m revolving credit facility and $1.45bn of term loans.
A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.
Chinese service provider WuXi PharmaTech has sold a 5.55% stake in its wholly owned CMO (contract manufacturing organization) subsidiary SynTheAll Pharmaceutical (STA) to members of STA’s and WuXi’s management for $28m.
Between May 2013, when Quintiles went public, and this week, newly public companies’ stocks in the biopharma outsourcing space have all seen their prices rise by more than 35%.
AbbVie’s proposed £31bn ($50bn) takeover of Shire is very likely “dead” after the US biopharma's board changed its recommendation and advised shareholders not to back the bid.
The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
Elder Pharmaceuticals has agreed to sell its branded drug portfolio to Torrent Pharmaceuticals in a deal that will refocus the firm as a CMO and anti-infectives producer.
Analysts from rating agency Moody's have upgraded their view of Quintiles, the world’s “largest pharmaceutical service provider,” from stable to positive.
CRO Quintiles and its shareholders are offering more than 19 million shares of common stock that will be priced between $36 and $40 per share, according to an updated S-1 filing with the US SEC.
It seems service quality really does mean bigger profits for CROs serving the pharma and biopharma industries, according to Industry Standard Research’s (ISR) new report.
Albany Molecular Research (AMRI) says ‘streamlining’ plan will focus on its drug licensing unit not its contract API research, development and manufacturing services division.
Outsourcing-Pharma presents its latest round-up of the comings and goings in the pharmaceutical sector, with breaking news from PPD whose CEO Raymond Hill has departed.
Express Script will take over fellow PBM Medco after a definitive merger agreement was unanimously approved by the boards of directors of both companies.
BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
Covance has added a 40,000 sq ft biotech laboratory to its site in Indiana, US site to support its relationship with Eli Lilly and boost capacity outside Europe.
Piramal Healthcare is planning to raise Rs 10bn ($218m) over the next six to eight months to fund overseas acquisitions, with the India-based company eying several sectors including contract research.
US drug discovery group Deltagen has acquired Benten BioServices, a contract services organisation that offers a suite of regulatory-compliant manufacturing and testing services to support biopharmaceutical development and commercialisation.
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
US CRO Life Science Research has become a private company with the completion of its acquisition by Lion Holdings, an investment vehicle owner by CEO Andrew Baker.
US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”
Shareholders have filed an $8bn (€5.7bn) lawsuit against Genzyme alleging that the company’s CEO “issued a series of materially false and misleading statements” about its manufacturing problems.
In the latest twist in an increasing bitter takeover battle, the Ontario Superior Court of Justice has rejected JLL’s bid to oust directors elected to the board of Canadian CMO Patheon in April.
Top 10 contract research organization (CRO) PharmaNet has gone into private hands following the conclusion of its acquisition by private equity firm JLL Partners.
The committee set up by Patheon to review the unsolicited bid by private equity firm JLL to take control of the firm has asked for advice on the legality of the move.
MDS has formed a special committee to improve shareholder value following poor results and pressure from investors to sell some of its business units, which include a CRO division.
Falling API sales and “an unprecedented negative economic environment” have forced Perrigo to cut its fiscal 2009 profit forecast and sent stock plummeting by 20 per cent.
Contract research organisation PharmaNet Development Group has found a buyer just a few weeks after saying it was considering placing itself on the block.
Contract development and manufacturing company Patheon received an unsolicited takeover bid from private equity firm JLL Partners ahead of reporting a return to profit in its fiscal fourth quarter results.
KV Pharmaceuticals’ long-serving CEO Marc Hermelin has either been sacked or has retired, depending on which party’s version of events one believes, and is being replaced by David Vliet CEO of the company’s Ethex division on an interim basis.
Packaging firm Chesapeake has become a visible casualty of the current economic climate, with the New York Stock Exchange (NYSE) suspending trading of its shares.
Contract research organisation Encorium has bought $250,000 of its own stock in a bid to stabilise its share price, which has been in steep decline in recent weeks.
Ranbaxy has claimed that a pharmaceutical company is making a
concerted effort to depress the company's share price by initiating
the accusations that the generics manufacturer falsified data to
achieve compliance.
Applera has announced its intentions to separate its Celera Group
from the Applera Corporation, forming a separate, publicly-traded
company, subject to approval from the US Securities and Exchange
Commission and Applera's board...
After seven months of offers, refusals and heated exchanges, it
seems an increased offer from Roche has finally persuaded the
powers that be at Ventana to sell up.
Harvard Bioscience has rejected an unsolicited acquisition offer
from Skystone Advisors to acquire all outstanding shares of common
stock in the life science tools and instrument manufacturer.
